# EDGAR Filing Document

**Accession Number:** 0001393052
**File Stem:** 0001393052-25-000058
**Filing Date:** 2025-8
**Character Count:** 11930
**Document Hash:** dc38bb6a759f6982a915d4867b7755da
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001393052-25-000058.hdr.sgml**: 20250818

**ACCESSION NUMBER**: 0001393052-25-000058

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 17

**CONFORMED PERIOD OF REPORT**: 20250813

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250818

**DATE AS OF CHANGE**: 20250818

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** VEEVA SYSTEMS INC
- **CENTRAL INDEX KEY:** 0001393052
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-PREPACKAGED SOFTWARE [7372]
- **ORGANIZATION NAME:** 06 Technology
- **EIN:** 208235463
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0131

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36121
- **FILM NUMBER:** 251226415

**BUSINESS ADDRESS:**
- **STREET 1:** 4280 HACIENDA DRIVE
- **CITY:** PLEASANTON
- **STATE:** CA
- **ZIP:** 94588
- **BUSINESS PHONE:** 925-452-6500

**MAIL ADDRESS:**
- **STREET 1:** 4280 HACIENDA DRIVE
- **CITY:** PLEASANTON
- **STATE:** CA
- **ZIP:** 94588

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** VERTICALS ONDEMAND INC
- **DATE OF NAME CHANGE:** 20070313

?xml version='1.0' encoding='ASCII'? veev-20250813

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**_____________________________________________________________________________**

**FORM 8-K** 

**_____________________________________________________________________________**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): August 13, 2025** 

**_____________________________________________________________________________**

![Veeva logo 1 for sec.jpg](veev-20250813_g1.jpg)

**Veeva Systems Inc.** 

**(Exact name of registrant as specified in its charter)**

**_____________________________________________________________________________**

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-36121** | **20-8235463** |
| **(State or other jurisdiction<br>of incorporation)** | **(Commission File Number)** | **(IRS Employer**<br>**Identification No.)** |

---

**4280 Hacienda Drive** 

**Pleasanton, California 94588** 

**(Address of principal executive offices, including zip code)**

**Registrant's telephone number, including area code: (925) 452-6500** 

**Not Applicable**

**(Former name or former address, if changed since last report)**

**_____________________________________________________________________________**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol** | **Name of each exchange on which registered** |
| Class A Common Stock,<br>par value $0.00001 per share | VEEV | New York Stock Exchange |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

---

| | |
|:---|:---|
| Emerging growth company | ☐ |
| If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. | ☐ |

---

------

**Item 7.01.&nbsp;&nbsp;&nbsp;&nbsp;Regulation FD Disclosure.**

On August 13, 2025, Veeva Systems Inc., a Delaware public benefit corporation ("Veeva"), entered into a settlement agreement with IQVIA Inc. ("IQVIA") that resolves all ongoing litigations between Veeva and IQVIA (the "Settlement Agreement"). As previously disclosed, Veeva and IQVIA have been involved in litigation since 2017. Under the terms of the Settlement Agreement, neither party will pay damages to the other party and both parties agree to dismiss with prejudice all claims and counterclaims currently pending. In connection with the Settlement Agreement, the parties have also entered into certain agreements to facilitate access to each other's data and software to provide certain products and services to mutual customers. Pursuant to previously disclosed, outcome-based fee arrangements with certain law firms that represented us in our litigations with IQVIA, we will be making a one-time payment of approximately $31 million to such law firms in connection with settlement of the litigations.

The information in this Item 7.01 and Exhibit 99.1 attached to this Current Report on Form 8-K is being furnished under Item 7.01 of Form 8-K. Such information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act.

**Item 9.01.&nbsp;&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits.**

(d)&nbsp;&nbsp;&nbsp;&nbsp;Exhibits.

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | <u>[P](ex991projectvalentinerelea.htm)[re](ex991projectvalentinerelea.htm)[ss Relea](ex991projectvalentinerelea.htm)[se, dated August 18, 2025](ex991projectvalentinerelea.htm)</u> |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | Veeva Systems Inc. | Veeva Systems Inc. |
| | By: | /s/ Josh Faddis |
| | | Josh Faddis |
| | | Senior Vice President, General Counsel |
| Dated: August 18, 2025 |  |  |

---

## Exhibit 99.1

![picture1.jpg](picture1.jpg)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;![image3.jpg](image3.jpg)

**IQVIA and Veeva Announce Long-term Clinical and Commercial Partnerships and Resolution of All Disputes**

*Global partnerships to help customers improve clinical and commercial efficiency and effectiveness*

**RESEARCH TRIANGLE PARK, N.C. and PLEASANTON, Calif. — August 18, 2025 —** IQVIA (NYSE: IQV) and Veeva Systems (NYSE: VEEV) today announced global clinical and commercial partnerships and the complete resolution of all pending legal disputes. Under the terms of the long-term agreement, customers can use software, data, technology, and service offerings from Veeva and IQVIA together in a simple and efficient way.

The global partnerships make it easy for customers to work with IQVIA and Veeva in key areas including:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Commercial**: The companies have established master data and software third-party access (TPA) agreements that allow IQVIA or Veeva data to be used with each other's software or services in customer instances, including the use of IQVIA data in Veeva Network for master data management (MDM), Veeva Nitro for analytics, and Veeva AI. In addition to the use of Veeva data in IQVIA's commercial products and services, IQVIA has also joined the Veeva Technology, AI, and Services Partner Programs to support customer integrations between Veeva software and IQVIA Analytics, IQVIA Information Management (including MDM), IQVIA Agentic AI, and IQVIA Commercial Orchestration offerings. With these partnerships and overall master agreements in place, customers also benefit from a fast, easy process to get TPAs for projects.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Clinical**: IQVIA has joined Veeva's CRO Clinical Data Partner program and can leverage the Veeva Clinical Suite to execute clinical trials using Veeva software products, including study builds with Veeva EDC. With this partnership, customers will benefit from IQVIA's clinical data management, clinical technology solutions, and EDC programming expertise with Veeva software to accelerate database builds, study locks, and data delivery.

"We are committed to supporting frictionless product and services integration with IQVIA for the benefit of our joint customers and the industry overall," said Veeva founder and CEO Peter Gassner. "I am excited about the potential for our clinical and commercial partnerships to create significant value for our shared customers."

"IQVIA and Veeva's partnerships bring together best-in-class capabilities in information, AI, technology, and services for our shared clients," said Ari Bousbib, chairman and CEO of IQVIA. "This will enable IQVIA customers on Veeva platforms to accelerate clinical development, bring treatments to market more efficiently, and improve access to innovations for patients."

For more information visit Veeva Partnerships on iqvia.com or IQVIA Partnerships on veeva.com.

**About IQVIA**

---

| | |
|:---|:---|
|® 2025 Veeva Systems Inc. All rights reserved. Veeva, V, Vault, and Crossix are registered trademarks of Veeva Systems Inc. | ![image3a.jpg](image3a.jpg) |

---

------

IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA's insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.

**About Veeva Systems**

Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.

**Veeva Forward-looking Statements**

This release contains forward-looking statements regarding the expected results and benefits from Veeva's partnerships with IQVIA. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements.

###

---

| | |
|:---|:---|
| **Contacts:** | |
| Maria Scurry<br>Veeva Media Relations<br>781-366-7617<br>maria.scurry@veeva.com | Alissa Maupin<br>IQVIA Media Relations<br>919-923-6785<br>alissa.maupin1@iqvia.com |
| <br>Gunnar Hansen<br>Veeva Investor Relations<br>267-460-5839<br>gunnar.hansen@veeva.com | Kerri Joseph<br>IQVIA Investor Relations<br>973-541-3558<br>kerri.joseph@iqvia.com |

---

---

| | |
|:---|:---|
|® 2025 Veeva Systems Inc. All rights reserved. Veeva, V, Vault, and Crossix are registered trademarks of Veeva Systems Inc. | ![image3a.jpg](image3a.jpg) |

---